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ABSTRACT 
Breast cancer (BC) is the most common cancer worldwide prevalent among women with more 
than one million cases and is second only to lung cancer. The identification of the sequences 
based on the unique tetramers GCAC, GTCA were selected from experimental work. The16 base 
pair DNA regulatory sequences of which the motifs  area part of containing these motif in genes 
impliocated in cancer 
CAGE1(AAGCTGTCATTA),BRCA1(GACTGAGTCAA),ABCB1(CTCTAAGTCAT),ABCB5
(GATATGTTAAAGC) and ABI1(CTTCTGGGAA)  were then selected as novel putative targets 
in breast cancer therapy based on their selectivity on the BC oncogenes which are not found in 
the normal human genome 1-23 and the sex chromosomes x and Y. 
 were obtained via computational analysis.possible  the in silico discovery of putative anti breast 
cancer targets of importance in the genome 
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INTRODUCTION 
 
       BC is the most common malignancy in women accounting for about 18% of female cancers 
worldwide and over half a million diagnosed each year. Its incidence increases with age. It was 
the second most common cancer in the world with over 1million new cases. In Nigeria, cancer 
cases have increased by 21% out of which 10% are BC(Jemal, Siegel et al. 2008) . 
       It originates in the cells of the breast and several genes bearing high-penetrance mutations 
have been implicated in inherited disposition to BC with BRCA1 and BRCA2 being the most 
important, BC susceptibility 
genes other than BRCA1 AND BRCA2 have been identified. These genes are in two categories: 
1) Genes with rare-moderate penetrance (CHEK2,ATM and BRIP) (The CHECK2 Breast 
Cancer Case Control Consortium, 2004). 
2) Genes with low penetrance allele(Consortium 2006). 
 
ABCB1 MDR1 gene encodes a well characterized trans membrane transporter  P-glycoprotein. It 
is expressed in cancer cells and involved in genomic instability of cancer cells, gene 
rearrangements and mutations. Permeability glycoprotein also known P-glycoprotein (P-gp; 
MDR1; ABCB1) is an efflux transporter which belongs to the ATP-bindingcassette (ABC) 
superfamily of transporters, and actively transport a wide range of structurally 
andmechanistically diverse endogenous and xenobiotic chemical agents across the cell 
membrane atthe energy expense of ATP hydrolysis (Chen et al., 2018).  P-glycoprotein has been 
implicated in the development of multidrug resistance to anticancer drugs when expressed  in 
breast cancer  cells (Clarke, Leonessa et al. 2005) due to its ability to  profoundly implicate the 
role of drug pharmacokinetics (PK) that can clinically alter the administrated drugefficacy or 
even lead to various adverse side-effects due to drug–drug interactions (DDIs) in the caseof 
polypharmacy (Selick et al., 2002; Montanari and Ecker, 2015; Chen et al., 2018). Presence of 
oestrogen  have been found to downregulate P-glcoprotein expression in ER positive BC cell 
lines (Imai, Ishikawa et al. 2005). 
CAGE1 has been identified and characterized as a novel cancer antigene   (Park, Lim et al. 
2003). 
   
 
 
5-10% of BC cases develop on a hereditary basis. Approximately 80% are accounted for by 
mutations in the BC susceptibility genes,BRCA1((40-45%) and BRCA2(35-40%).The remaining 
20% of BCs may be due to mutations in other tumor suppressor genes as P53,PTEN and ATM in 
addition to other genes. Genetic events involved in BC tumor formation are as follows: tumor 
oncogene activation, 
Tumor suppressor gene inactivation, abnormal protein over expression and multiple gene 
alteration(Hudson, Anderson et al. 2010) . 
  
  Systemic treatment options include cytotoxic, hormonal and immunotherapeutic agents 
(Burton, Clayton et al. 2007).In addition, surgery, radiotherapy, hormonal therapy, biological 
therapy as well as chemotherapy. The chemotherapeutic interventions are used in adjuvant, 
neoadjuvant, and metastatic settings. In general, systemic agents are active at the beginning of 
the therapy in 90% of primary BC cases and 50% of metastatic settings. However, after a 
variable period of time, progression occurs. Resistance to therapy occurs at this point. Most of 
the existing drugs are toxic, non specific and have severe side effects  (Hortobagyi 1998), many 
tumor develop resistance to majority of the chemotherapeutic agents.  
Estrogen receptors ERs are dependent, inducible signal transducers  which act through a  
nonclassical pathway in which liganded ERs are tethered to DNA via association with other 
transcription factor complexes including Fos/Jun [activator protein-1 (AP-1)–responsive 
elements] or SP-1(Kushner, Agard et al. 2000, Saville, Wormke et al. 2000) They are capable of 
binding to palindromic DNA sequences 5′-TGAGTCA-3′ as well as similar sequences 5′-
TTAGTCA-3′ and 
5′-TGATTCA-3′(Lee, Hahn et al. 2000, Papassava, Gorgoulis et al. 2004) 
 A small number of genes containing an AP-1 site in their promoters have been shown to be 
regulated by ERs(Schmitt, Bausero et al. 1995) . AP-1  can be induced by extracellular stimuli 
such as cytokines, UV radiation, growth factors, oxidative stress, and carcinogens can and 
promote AP-1 binding to the TRE of its target genes that are involved in cell growth, 
inflammatory responses, and repair processes. 
In cellular and viral genes, the AP-1 transcription factor is thus a  major component of many 
signal transduction pathways. It is a complex  dimer of homo- and heterodimer family members. 
The regulation of AP-1 target genes is regulated by AP-1 transcription factor via binding to the 
DNA regulatory sequence 12. The response TPA element sequence GCAC or GTCA are 
therefore bound by c-Jun homodimers and c-Jun/c-Fos heterodimers (Van Dam and Castellazzi 
2001).  
In this research work, DNA regulatory sequence motifs containing the unique tetramer GCAC, 
GTCA have been curated from experimental work and  
The post genomic era characterized by the completion of the human genome project, the start of 
both the proteomics and structural genomics revolutions and the development in information 
technology have resulted in the use of structure based drug design in the discovery of  new drug 
targets. The human genome is the complete set of genetic information for humans (Homo 
sapiens). This information is encoded as DNA sequences within the 23 chromosome pairs (22 
pairs being homologous) in cell nuclei and in a small DNA molecule found in the mitochondria. 
It includes both the protein-coding genes as well as the non-coding genes. The haploid human 
genome (contained in the spermatozoa and oocyte) consist of three billion DNA base pairs while 
the diploid genomes found in somatic cells have twice the c content (Guerzoni and McLysaght 
2011) There is an urgent need to identify novel putative targets into the breast cancer drug 
development pipeline as an early intervention method in breast cancer therapy . In silico 
intervention at various stages in the drug discovery cycle is equipped with the potentials to 
reduce both time and cost involved in the process  (Collins, Patrinos et al. 1998)  The interaction 
between small molecules and DNA is important due to its implication in the regulation of gene 
expression by activators and repressors in vivo (Paleček, Fojta et al. 1998) 
DNA as a drug target in the case of infectious agents  and  that of the human as in BC have 
proved attractive due to the availability of the three dimensional DNA structures and the 
 
 
predictability of their accessible chemical functional 
In view of the availability of such  novel targets which to which selective chemotherapeutic 
agents against BC can be developed,  40% still die ultimately from the disease. These warrant the 
need for the development of novel therapeutic agents in the treatment of BC via identification of  
potential drug targets. 
Method 
The entire Human genome was downloaded via the file transfer protocol ftp from the database of 
the National Centre for Biotechnology Information (NCBI)  ftp site . 
Homo_Sapiens.NCBI34.pep.fa.downloaded from ftpsite (ftp.// 
ftp.ensembl.org/pub/current_human/data/fasta/pep/). The download was done in the fasta format. 
The oncogenes BRCA, CAGE1, ABCB5 and ABI1 were also downloaded  from the Online 
Mendelian Inheritance In Man was also downloaded from the website where OMIM is 
domiciled. 
https://bioportal.bioontology.org/ontologies/OMIM . The selectivity of the oncogenes as 
potential target agents was ascertained when the sequence frequency of occurrence in the human 
genome was determined.  
 
Results 
Table 1.0 Summary of selected oncogenes, start/stop positions on the specific chromosome, gene 
sequence and the base pair number  
Gene 
Name 
Length Transcription 
Factor 
Chromosome 
Number 
Binding 
Position 
Base pairs BP no 
BRCA1 26 AP-1 Chr7 41267898-
41267908- 
GACTGAGTCA
A 
11 
CAGE 1 3 TGIF Chr6 7405451-
7405462 
AAGCTGTCAT
TA 
12 
ABCB1  AP-1 Chr7 87336139-
87336149 
CTCTAAGTCA
T 
11 
       
 
 
 
 
Table 2.0 16base pair sequences as potential drug targets from 11bp BRCA1  
Gene Name    
BRCA1 GACTGAGTCAA 11 615 
 TGACTGAGTCAA 12 197 
 ATGACTGAGTCAA 13 75 
 TATGACTGAGTCAA 14 14 
 TTATGACTGAGTCAA 15 4 
 GTTATGACTGAGTCAA 16 2 
 TGTTATGACTGAGTCAA 17 2 
 CTGTTATGACTGAGTCAA 18 1 
 
 
 
Table 3.0 16base pair sequences as potential drug targets from 11base pair sequence of CAGE1  
 
    
CAGE1 AAGCTGTCATTA 12 328 
 
 
 AAAGCTGTCATTA 13 122 
 AAAAGCTGTCATTA 14 37 
 TAAAAGCTGTCATTA 15 9 
 ATAAAAGCTGTCATTA 16 5 
 CATAAAAGCTGTCATTA 17 1 
Table 4.0 16base pair sequences as potential drug targets from  11base pair of ABCB1 oncogene 
 
    
ABCB1 CTCTAAGTCAT 11 810 
 ACTCTAAGTCAT 12 199 
 AACTCTAAGTCAT 13 63 
 CAACTCTAAGTCAT 14 13 
 CCAACTCTAAGTCAT 15 6 
 GCCAACTCTAAGTCAT 16 3 
 TGCCAACTCTAAGTCAT 17 2 
 TTGCCAACTCTAAGTCAT 18 1 
 
Discussion 
The selected genes have been ABCB1, CAGE1 and BRCA1 have been implicated in the 
proliferation and development of cancer cells. The  base pairs numbers  of these genes are as 
follows 11 badse pairs for  BRCA1 and ABCB1 while CAGE1 has 12 base pairs Table 1.0. The 
sequences contain GCAC and GTCA which are unique tetramers however the frequency of 
occurrence of the sequences 615 for BRCA1 Table 2.0 ABCB1 11 base pair CTCTAAGTCAT   
occurs at a frequency of  810 in the human genome while CAGE1 with 12 base pairs 
AAGCTGTCATTA occurs  328 times.  The  criteria  for an ideal target is that it must occur in a 
frequency of 1 for it to be non toxic that is it must be a single copy gene. Therefore to obtain a 
single copy gene from  these oncogenes, the start and stop positions wereidentified  such that the 
the sequences to the right and left of the core sequences were determined Table 2.0,3.0 and 4.0. 
Thus stepwise, the final 16base pairs.  The single copy base pairs which will be potential drug 
targets as anticancer drugs were finally obtained as CTGTTATGACTGAGTCAA, CAGE1 with 
the 17base pairs CATAAAAGCTGTCATTA  and ABCB1 TTGCCAACTCTAAGTCAT . 
Conclusion 
Potential anti breast cancer targets which will go a long way when drugs are developed against 
them include  
CTGTTATGACTGAGTCAA, CAGE1 with the 17base pairs CATAAAAGCTGTCATTA  and 
ABCB1 TTGCCAACTCTAAGTCAT .Further research work based on drug design techniques 
will be a be developed. 
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